In the United States, approximately 35 million adults suffer from CIC, making it one of the most common gastrointestinal (GI) complaints, accounting for more than 6.5 million office visits per year. This enduring webcast focuses on increasing learners’ ability to integrate changes into their practices and improve CIC and IBS-C management in their patients.

  • Identify symptoms specific to CIC to distinguish it from IBS-C.
  • Diagnose CIC or IBS-C based on patients’ presenting symptoms.
  • Describe the Rome IV criteria for CIC and IBS-C, and demonstrate how disease severity affects patient QoL.
  • Recognize the clinical guidelines for non-pharmacologic and pharmacologic options to treat patients with CIC and IBS-C.

Registration



Pre-Test


Which is generally not a symptom of chronic idiopathic constipation (CIC)?

On average, how many days per month do symptoms of IBS-C and CIC interfere with patients’ productivity?

When should pharmacologic therapy be considered in patients with IBS-C and CIC?

How confident are you in your ability to manage formulary decisions and incorporate best practices for the treatment of patients with rare/orphan diseases?

How confident are you in your ability to identify symptoms and diagnose IBS-C and CIC?

How confident are you in describing the Rome IV criteria and how disease severity affects patient QoL?

How confident are you in applying clinical guidelines for the treatment of IBS-C and CIC (pharmacologic and non-pharmacologic)?